One of them is miR-34a, which was demonstrated to increase resistance to docetaxel (DTX) in luminal BC cells, probably through inhibition of cyclin D1 (CCND1) and B-cell lymphoma 2 (BCL-2), then inducing G1 arrest and blocking DTX effectiveness as a consequence [21]. Here, BCL2 is linked to breast cancer.